Literature DB >> 8974793

Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease.

B Nsiri1, N Gritli, F Bayoudh, T Messaoud, S Fattoum, S Machghoul.   

Abstract

Abnormalities of coagulation and fibrinolysis were studied in a group of 28 children and young adults with homozygous sickle cell disease (SCD), either in the steady state (n = 12) or during painful crisis (n = 16). Coagulation was explored by standard clotting tests and by measurement of prothrombin complex factors, factor VIII (VIII:C) and antithrombin III (ATIII), protein C (PC) and protein S (PS) activities, while fibrinolytic potential was evaluated using D-dimer, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) assays. In SCD patients, thrombin time (TT) was constantly shortened, both in the steady state (ratio to control 0.83 +/- 0.08, p < 0.0001) and in crisis (0.76 +/- 0.06, p < 0.0001). Mean levels of prothrombin complex were similar in asymptomatic patients to those in controls, but were significantly decreased during sickle cell crisis (p < 0.05 for factor V and p < 0.0001 for factors II, VII and X). Factor VIII:C was significantly increased, both in the steady state (207 +/- 35%, p < 0.0001) and during crisis (208 +/- 34%, p < 0.0001). PS activity was reduced int he steady state (81 +/- 12%, p < 0.01) and further diminished in crisis (68.5 +/- 27.5%, p < 0.001), while D-dimers were significantly elevated during sickle cell crisis (1028 +/- 675 ng/ml, p < 0.001). In all SCD patients, baseline levels of t-PA antigen were comparable to those in controls, whereas concentrations of PAI-1 antigen were significantly increased, either in the steady state (89.7 +/- 26.3 ng/ml, p < 0.0001) or in crisis (75.0 +/- 24.8 ng/ml, p < 0.0001). These results provide evidence for the presence of circulating activated clotting factors in SCD and for an imbalance of the profibrinolytic and antifibrinolytic systems most likely due to increased PAI-1 levels.

Entities:  

Mesh:

Year:  1996        PMID: 8974793     DOI: 10.1007/s00282-996-0279-2

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  18 in total

Review 1.  Physiological responses of sickle cell trait carriers during exercise.

Authors:  Philippe Connes; Harvey Reid; Marie-Dominique Hardy-Dessources; Errol Morrison; Olivier Hue
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

2.  Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).

Authors:  Nitin Patel; Nambirajan Sundaram; Mingyan Yang; Catherine Madigan; Vijay K Kalra; Punam Malik
Journal:  J Biol Chem       Date:  2010-03-29       Impact factor: 5.157

3.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

Review 4.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

5.  Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities.

Authors:  Javeed Dar; Inam Mughal; Hilali Hassan; Taj E Al Mekki; Zivani Chapunduka; Imad S A Hassan
Journal:  Ger Med Sci       Date:  2010-10-08

6.  Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia.

Authors:  Caterina P Minniti; Kara-Marie H Delaney; Alexander M Gorbach; Dihua Xu; Chyi-Chia Richard Lee; Nitin Malik; Antony Koroulakis; Matthew Antalek; Jordan Maivelett; Marlene Peters-Lawrence; Enrico M Novelli; Sophie M Lanzkron; Karen C Axelrod; Gregory J Kato
Journal:  Am J Hematol       Date:  2013-09-19       Impact factor: 10.047

Review 7.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

Review 8.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

9.  Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease.

Authors:  A L Akinyoola; I A Adediran; C M Asaleye; A R Bolarinwa
Journal:  Int Orthop       Date:  2008-07-17       Impact factor: 3.075

10.  Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.

Authors:  Jennifer O Nwankwo; Thomas Gremmel; Anja J Gerrits; Farha J Mithila; Rod R Warburton; Nicholas S Hill; Yunzhe Lu; Lauren J Richey; Joseph A Jakubowski; Andrew L Frelinger; Athar H Chishti
Journal:  Thromb Res       Date:  2017-10-26       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.